TC BioPharm (Holdings) Ltd Financials

TCBPY

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2024 Currency USD FYE December

This page shows TC BioPharm (Holdings) Ltd (TCBPY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 0/100

Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of TC BioPharm (Holdings) Ltd's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Returns

TC BioPharm (Holdings) Ltd generates a -402.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.

Earnings Quality Low Quality

1.03x

For every $1 of reported earnings, TC BioPharm (Holdings) Ltd generates $1.03 in operating cash flow (-$15.8M OCF vs -$15.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$15.3M

TC BioPharm (Holdings) Ltd reported -$15.3M in net income in fiscal year 2024.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$1.5M

TC BioPharm (Holdings) Ltd held $1.5M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

1.99B

TC BioPharm (Holdings) Ltd had 1.99B shares outstanding in fiscal year 2024.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-402.6%

TC BioPharm (Holdings) Ltd's ROE was -402.6% in fiscal year 2024, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

TCBPY Income Statement

Metric	FY24
Revenue	N/A
Cost of Revenue	N/A
Gross Profit	N/A
R&D Expenses	N/A
SG&A Expenses	N/A
Operating Income	N/A
Interest Expense	N/A
Income Tax	N/A
Net Income	-$15.3M
EPS (Diluted)	N/A

TCBPY Balance Sheet

Metric	FY24
Total Assets	N/A
Current Assets	N/A
Cash & Equivalents	$1.5M
Inventory	N/A
Accounts Receivable	N/A
Goodwill	N/A
Total Liabilities	N/A
Current Liabilities	N/A
Long-Term Debt	N/A
Total Equity	$3.8M
Retained Earnings	N/A

TCBPY Cash Flow Statement

Metric	FY24
Operating Cash Flow	-$15.8M
Capital Expenditures	N/A
Free Cash Flow	N/A
Investing Cash Flow	N/A
Financing Cash Flow	N/A
Dividends Paid	N/A
Share Buybacks	N/A

TCBPY Financial Ratios

Metric	FY24
Gross Margin	N/A
Operating Margin	N/A
Net Margin	N/A
Return on Equity	-402.6%
Return on Assets	N/A
Current Ratio	N/A
Debt-to-Equity	N/A
FCF Margin	N/A

Similar Companies

Thc Farmaceutica CBDG

$435K

Chitogenx CHNXF

$424K

Viracta Therapeutics Inc VIRX

$6.0M

Therapeutic Solutions Intl Inc TSOI

$512K

Havn Life Scienc HAVLF

$326K

Frequently Asked Questions

Is TC BioPharm (Holdings) Ltd profitable?

No, TC BioPharm (Holdings) Ltd (TCBPY) reported a net income of -$15.3M in fiscal year 2024.

What is TC BioPharm (Holdings) Ltd's return on equity (ROE)?

TC BioPharm (Holdings) Ltd (TCBPY) has a return on equity of -402.6% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is TC BioPharm (Holdings) Ltd's operating cash flow?

TC BioPharm (Holdings) Ltd (TCBPY) generated -$15.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

How many shares does TC BioPharm (Holdings) Ltd have outstanding?

TC BioPharm (Holdings) Ltd (TCBPY) had 1.99B shares outstanding as of fiscal year 2024.

What is TC BioPharm (Holdings) Ltd's cash runway?

Based on fiscal year 2024 data, TC BioPharm (Holdings) Ltd (TCBPY) had $1.5M in cash against an annual operating cash burn of $15.8M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Are TC BioPharm (Holdings) Ltd's earnings high quality?

TC BioPharm (Holdings) Ltd (TCBPY) has an earnings quality ratio of 1.03x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is TC BioPharm (Holdings) Ltd?

TC BioPharm (Holdings) Ltd (TCBPY) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.